Chronic diseases such as cardiovascular disease, metabolic disorders, neurodegenerative conditions, and cancer represent the major causes of morbidity and mortality worldwide. Although chronological age is one of the strongest predictors of disease risk, individuals of the same chronological age often exhibit dramatically different health trajectories.
This variability reflects differences in biological aging processes that influence tissue function, metabolic health, immune regulation, and cellular repair mechanisms. In recent years, researchers have increasingly explored biological aging biomarkers as tools for assessing physiological health and disease risk — capturing molecular and cellular changes associated with aging processes before overt disease symptoms appear.
Among the most widely studied biomarkers are epigenetic aging markers derived from DNA methylation patterns, which have been associated with multiple health outcomes including mortality risk, cardiovascular disease, and cognitive decline.
Biological Aging and Disease Development
Aging is the primary risk factor for many chronic diseases. The mechanisms underlying this association are complex and involve multiple biological pathways. The hallmarks of aging framework, first described by López-Otín and colleagues, identifies several interconnected biological processes that contribute to aging and disease development:
- Genomic instability and DNA damage accumulation
- Epigenetic alterations including DNA methylation drift
- Telomere shortening and replicative senescence
- Mitochondrial dysfunction and bioenergetic decline
- Cellular senescence and SASP-driven inflammation
- Stem cell exhaustion and impaired tissue regeneration
- Chronic low-grade inflammation (inflammaging)
These mechanisms influence tissue function and physiological resilience. As they accumulate over time, they increase susceptibility to chronic diseases. Importantly, the rate at which these processes progress varies across individuals due to genetic variation, lifestyle behaviors, environmental exposures, and medical history.
The same chronological age can correspond to dramatically different biological ages — and it is biological age, not the calendar, that most accurately predicts disease risk and healthspan trajectory.
Epigenetic Aging Biomarkers and Disease Risk
DNA methylation-based biological age estimators — often referred to as epigenetic clocks — have been shown to correlate with multiple health outcomes. Several studies have demonstrated associations between accelerated epigenetic aging (where biological age exceeds chronological age) and increased risk of:
- Cardiovascular disease and coronary artery disease
- Metabolic syndrome and type 2 diabetes
- Cognitive decline and neurodegenerative conditions
- All-cause mortality
One of the most widely studied epigenetic clocks, GrimAge, was specifically designed to predict lifespan and healthspan by integrating methylation biomarkers associated with plasma proteins and smoking exposure. Research has shown that GrimAge acceleration strongly predicts mortality risk and age-related disease outcomes.
Implications for Preventive Medicine
Preventive medicine aims to identify individuals at elevated risk for disease and implement interventions that reduce that risk. Traditional risk assessment models incorporate factors such as blood pressure, cholesterol levels, body mass index, smoking status, and family history.
Biological aging biomarkers may complement these traditional measures by providing insight into underlying physiological aging processes. By integrating biological age measurements with conventional risk assessments, clinicians may gain a more comprehensive understanding of patient health trajectories — particularly for preventive medicine programs, longevity clinics, and research focused on aging-related disease.
The XELGEN platform analyzes genome-wide DNA methylation patterns to estimate biological age and evaluate epigenetic biomarkers associated with aging processes. By integrating epigenetic biomarker analysis into clinical or research settings, physicians and scientists may gain additional insight into molecular aging processes that influence health outcomes.
Request Clinical AccessCan biological age biomarkers predict disease risk?
Research suggests that certain biological aging biomarkers are associated with increased risk of chronic diseases and mortality. However, these biomarkers should be interpreted alongside traditional clinical assessments and are not diagnostic tools on their own.
References
- Lu AT et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY). 2019.
- Levine ME et al. Epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018.
- López-Otín C et al. The hallmarks of aging. Cell. 2013.DOI
